Related Experiment Video
Updated: Apr 27, 2026
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
16.2K
Association between 5-HTTLPR polymorphism and Parkinson's disease: a meta analysis.
1Department of Neurology, The Fourth Affiliated Hospital of China Medical University, No. 4 East Chongshan Road, Huanggu District, Shenyang, 110032, China, lianbogao@126.com.
Molecular Biology Reports
|June 29, 2014
Summary
This meta-analysis found no significant genetic link between the serotonin transporter gene promoter polymorphism (5-HTTLPR) and Parkinson's disease (PD) or depression in PD patients. A potential association was noted in Asian subgroups, warranting further investigation.
Area of Science:
- Genetics
- Neuroscience
- Psychiatry
Background:
- The serotonin transporter gene promoter polymorphism (5-HTTLPR) is studied for its role in neurological and psychiatric conditions.
- Parkinson's disease (PD) is often accompanied by depression, suggesting potential shared genetic factors.
Purpose of the Study:
- To conduct a meta-analysis investigating the association between 5-HTTLPR and Parkinson's disease (PD).
- To examine the relationship between 5-HTTLPR and depression in individuals with PD.
Main Methods:
- A systematic literature search identified relevant association studies.
- Meta-analysis was performed using random-effect models to calculate pooled odds ratios for genotype and allele frequencies.
- Biallelic models, including the biallelic dominant model (BDM), were applied.
Main Results:
- Overall meta-analysis revealed no significant association between 5-HTTLPR and PD or depression in PD.
- A moderate negative association was observed between 5-HTTLPR and PD in the Asian subgroup using the BDM approach.
- Only six studies met the criteria for PD association, and three for PD with depression.
Conclusions:
- The current meta-analysis does not support a direct primary effect of 5-HTTLPR on the risk of PD or depression in PD patients.
- Further large-scale studies are needed, considering allelic variants, ethnic variations, and gene-gene interactions for definitive conclusions.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
22
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
22
01:24Parkinson Disease l: Introduction
21
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
21
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157